Literature DB >> 14745286

Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea?

Byung-Cheol Song1, Dong Jin Suh, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee.   

Abstract

BACKGROUND AND AIMS: Although hepatitis B e antigen (HBeAg) loss after interferon-alpha (IFN-alpha) therapy in patients with chronic hepatitis B is durable in whites, frequent relapse of hepatitis B virus (HBV) has been reported in endemic areas. This study was to evaluate the durability of interferon-induced HBeAg loss and find the risk factors for relapse.
METHODS: We retrospectively analyzed 32 patients with IFN-alpha-induced HBeAg loss. They were followed up to 50 months. Age, sex, presumed route of infection, pretreatment levels of serum alanine aminotransferase and HBV DNA, and histologic findings were evaluated as potential risk factors for relapse.
RESULTS: The cumulative relapse rates at 1-, 2- and 3-year were 25.5%, 35.7%, and 43.5%, respectively. They were higher in the older patients (>37 years) than in the younger ones (43.5% vs. 6.7% at 1-year, 50.6% vs. 20% at 2-year, and 64.7% vs. 20% at 3-year; P = 0.017). Patients with presumed vertical HBV infection tended to have a higher relapse rate (P = 0.11). Old age and presumed vertical infection were 2 independent risk factors for relapse.
CONCLUSION: Relapse after IFN-alpha-induced HBeAg loss was common in this endemic area, especially in old patients and in those with presumed vertical HBV infection. Intensive surveillance and other therapeutic modalities would be necessary for these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745286     DOI: 10.1097/00004836-200402000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.

Authors:  H J Flink; E H C J Buster; I Merican; F Nevens; G Kitis; J Cianciara; R A de Vries; B E Hansen; S W Schalm; H L A Janssen
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 2.  Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

Authors:  Matthias Girndt
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Authors:  Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

Review 4.  Liver physiology and liver diseases in the elderly.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.